secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001193125-23-230786
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics appoints CFO Lucy Day as Principal Accounting Officer; VP Controller departs
--------------------------------------------------------------------------------

- Lucy Day, current CFO, adds role of Principal Accounting Officer effective September 1, 2023.
- Michael Nazak, Vice President & Corporate Controller, to depart on September 15, 2023.
- Annie Yoshiyama hired as new Vice President, Finance and Corporate Controller.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/d514862d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-230786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer